You are here: Home » PTI Stories » National » News
Business Standard

Dr Reddy's launches generic hepatitis C drug in India

Press Trust of India  |  New Delhi 

Dr Reddy's Laboratories today said it has launched a generic version of Sofosbuvir 400 mg and Velpatasvir 100 mg fixed-dose combination, indicated for the treatment of chronic hepatitis C, in the country.

The Hyderabad-based firm has launched its generic product under the brand name Resof Total, Dr Reddy's Laboratories said in a statement.



Dr Reddy's product is a generic version of Gilead's brand Epclusa.

"Treatment with this combination achieves a cure rate of more than 90 per cent in all genotypes of Hepatitis C virus," the company said.

of the company ended 3.54 per cent up at Rs 2,676.15 on

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

RECOMMENDED FOR YOU

Dr Reddy's launches generic hepatitis C drug in India

Dr Reddy's Laboratories today said it has launched a generic version of Sofosbuvir 400 mg and Velpatasvir 100 mg fixed-dose combination, indicated for the treatment of chronic hepatitis C, in the country. The Hyderabad-based firm has launched its generic product under the brand name Resof Total, Dr Reddy's Laboratories said in a statement. Dr Reddy's product is a generic version of Gilead's brand Epclusa. "Treatment with this combination achieves a cure rate of more than 90 per cent in all genotypes of Hepatitis C virus," the company said. Shares of the company ended 3.54 per cent up at Rs 2,676.15 on BSE. Dr Reddy's Laboratories today said it has launched a generic version of Sofosbuvir 400 mg and Velpatasvir 100 mg fixed-dose combination, indicated for the treatment of chronic hepatitis C, in the country.

The Hyderabad-based firm has launched its generic product under the brand name Resof Total, Dr Reddy's Laboratories said in a statement.

Dr Reddy's product is a generic version of Gilead's brand Epclusa.

"Treatment with this combination achieves a cure rate of more than 90 per cent in all genotypes of Hepatitis C virus," the company said.

of the company ended 3.54 per cent up at Rs 2,676.15 on

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Dr Reddy's launches generic hepatitis C drug in India

Dr Reddy's Laboratories today said it has launched a generic version of Sofosbuvir 400 mg and Velpatasvir 100 mg fixed-dose combination, indicated for the treatment of chronic hepatitis C, in the country.

The Hyderabad-based firm has launched its generic product under the brand name Resof Total, Dr Reddy's Laboratories said in a statement.

Dr Reddy's product is a generic version of Gilead's brand Epclusa.

"Treatment with this combination achieves a cure rate of more than 90 per cent in all genotypes of Hepatitis C virus," the company said.

of the company ended 3.54 per cent up at Rs 2,676.15 on

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22